ARVN SEC Filings: 8-K, 10-Q, S-3 & 424B – Arvinas

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 11, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 24, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Arvinas Reports Third Quarter 2026 Financial Results and Corporate Updates

Nov 3, 2026

8-K

Arvinas Reports Second Quarter 2026 Financial Results and Regulatory Approval of VEPPANU

Aug 4, 2026

8-K

Arvinas, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 25, 2026

8-K

Arvinas, Inc. Announces Departure of Chief Medical Officer Noah Berkowitz

Jun 22, 2026

8-K

Arvinas and Pfizer Finalize License Agreement with Rigel Pharmaceuticals for VEPPANU™

Jun 16, 2026

8-K

Arvinas Announces Pipeline Re-prioritization and ARV-806 Strategy

Jun 2, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

Shares of our common stock having an aggregate offering price of up to $300,000,000.-

Aug 6, 2021

424B5

Common Stock-

Aug 6, 2021

424B5

5,714,286 Shares-

Dec 16, 2020

424B5

Gain on Sale, Exchange or Other Taxable Disposition of Our Common Stock-

Dec 14, 2020

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Nov 7, 2019

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Nov 6, 2019

Registrations

TYPE

HEADLINE

FILED AT

S-3

November 2026 SHELF + ATM

Nov 3, 2026

S-8